Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Osimertinib (TAGRISSO) (ROSY-T)

Trial Identifier:	D5161N00007
Sponsor:	AstraZeneca
Collaborator:	Parexel
NCTID::	NCT05629234
Start Date:	March 2023
Primary Completion Date:	March 2026
Study Completion Date:	March 2026
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.